​Pharmacology- Carbidopa

​Pharmacology-  Carbidopa
Parkinsonism is treated with levodopa; however, the drug is metabolized by DOPA decarboxylase in the gastrointestinal tract and the periphery, which results in a lower dose being available to the central nervous system. In addition to this, the dopamine that is produced has unintended consequences.


Dopamine decarboxylase is inhibited by carbidopa, which increases the availability of levodopa to the central nervous system (CNS) and decreases the dopamine-mediated adverse effects of levodopa.

The process of absorbing, distributing, and eliminating
Within the context of Parkinsonism treatment, it is typically administered in conjunction with levodopa. Considering that carbidopa is unable to pass through the blood-brain barrier, its effects are limited to the peripheral metabolism of levodopa.

Use in Clinical Settings 
A supplement that is used in the treatment of Parkinson.

Negative consequences 
Dry mouth, hypersensitivity responses, hypotension, and brief drowsiness are some of the symptoms that may occur.